ÂÜÀòÉÙÅ®

The ESH 4th Translational Research Conference on Chronic Lymphocytic Leukaemia proposes a programme of leading-edge basic and clinical science, as well as opportunities for informal scientific interaction with a panel of global experts in the field. The presentation of new data is encouraged, as well as spirited debates on how to use this knowledge to the future of CLL therapy. Chairs: Jennifer Brown, Paolo Ghia, Michael Hallek

This translational research conference fosters scientific exchange between laboratory scientists and clinicians working on translational CLL research worldwide. It provides opportunities for education and international networking to basic and clinical scientists, including those still in-training.

A first-class selection of international speakers will guarantee the highest quality of science and a summary of the most recent developments in the biology and therapy of CLL.

This educational conference has been approved for 17 CME-CPD credit points by the European Board for Accreditation in ÂÜÀòÉÙÅ® (EBAH)!

Why the meeting will be valuable for participants?

– It fosters scientific exchange between laboratory scientists and clinicians working on translational CLL research worldwide

– It provides opportunities for leading-edge education and international networking to basic and clinical scientists, including those still in-training

– A first-class selection of international speakers will guarantee the highest quality of science and a summary of the most recent developments in the biology and therapy of CLL.

Scientific Topics:

– Spectrum of CLL – one disease or more

– Richter transformation

– Drivers of disease progression – from genetics, epigenetics, and proteomics (complexity of the evolution)

– The microenvironment of CLL

– Time limited therapies: which combination? which duration? which markers to stop therapy?

– BTK inhibition or degradation?

– The new challenge: resistance to one or two inhibitor classes? – Double refractory CLL

– Future therapies, new compounds

– Directions and strategies to use the best agents in the optimal way: sequencing, combinations, costs of therapy, availability

The programme will include:

– Plenary Sessions

– Brief Oral Communications

– Debates

– Panel Discussions

– Poster Walks

– Meet the Expert Sessions

– Brief Oral Communications

– Ample time for in-depth discussion

The meeting will be of interest to:

• Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)

• Junior scientists and clinicians (MD, PhD)

• PhD candidates and clinical residents still in-training

Learning Objectives:

Upon completion of this CME activity, participants should:

– Understand recent advances in elucidating the pathogenesis of CLL

– Describe recent data on therapeutic regimens for CLL

– Understand emerging data on mechanisms of resistance to targeted agents in CLL

– Understand the debate about how best to optimize CLL therapy in the future

Register

Direct email queries to: [email protected]